NEW YORK (GenomeWeb News) – Genomics-based prostate cancer test developer GenomeDx Biosciences today said that it closed a Series B financing round.

The San Diego-based company declined to disclose the amount raised. Merck Global Health Innovation Fund led the round and was joined by Baird Capital Partners, Aeris Capital, and CD Ventures. The funding will go toward expanding the commercialization of GenomeDx's Decipher prostate cancer test, which predicts the risk of developing the disease independent of a PSA test and other commonly used assessment tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.